List of Excipients in API umbralisib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing umbralisib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| TG Therapeutics Inc | UKONIQ | umbralisib | 73150-200 | CELLULOSE, MICROCRYSTALLINE | 2035-05-26 |
| TG Therapeutics Inc | UKONIQ | umbralisib | 73150-200 | CROSCARMELLOSE SODIUM | 2035-05-26 |
| TG Therapeutics Inc | UKONIQ | umbralisib | 73150-200 | FD&C BLUE NO. 1 | 2035-05-26 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for umbralisib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
umbralisib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
umbralisib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
umbralisib drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 5
umbralisib drug variants containing FD&C YELLOW NO. 5
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing FD&C YELLOW NO. 5
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
umbralisib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL BETADEX
umbralisib drug variants containing HYDROXYPROPYL BETADEX
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing HYDROXYPROPYL BETADEX
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
umbralisib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
umbralisib drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
umbralisib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYDEXTROSE
umbralisib drug variants containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 8000
umbralisib drug variants containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
umbralisib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
umbralisib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| TG Therapeutics Inc | umbralisib | 73150-200 |
| >Company | >Ingredient | >NDC |
umbralisib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch